The role of programed death-ligand 1 in renal diseases

References

• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–330.
   PubMed Web of Science ®Google Scholar
• Chen J, Jiang CC, Jin L, et al. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. 2016;27:409–416.
   PubMed Web of Science ®Google Scholar
• Wang H, Kaur G, Sankin AI, et al. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol. 2019;12:59.
   PubMed Web of Science ®Google Scholar
• Franceschini D, Paroli M, Francavilla V, et al. PD-L1 negatively regulates CD4 + CD25 + Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest. 2009;119:551–564.
   PubMed Web of Science ®Google Scholar
• Hutchins NA, Wang F, Wang Y, et al. Kupffer cells potentiate liver sinusoidal endothelial cell injury in sepsis by ligating programmed cell death ligand-1. J Leukoc Biol. 2013;94:963–970.
   PubMed Web of Science ®Google Scholar
• Celada LJ, Kropski JA, Herazo-Maya JD, et al. PD-1 up-regulation on CD4(+) T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-beta1 production. Sci Transl Med. 2018;10:eaar8356.
   PubMed Web of Science ®Google Scholar
• Lomas-Neira J, Monaghan SF, Huang X, et al. Novel role for PD-1:PD-L1 as mediator of pulmonary vascular endothelial cell functions in pathogenesis of indirect ARDS in mice. Front Immunol. 2018;9:3030.
   PubMed Web of Science ®Google Scholar
• Pittet CL, Newcombe J, Prat A, et al. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. J Neuroinflammation. 2011;8:155.
   PubMed Web of Science ®Google Scholar
• Colli ML, Hill J, Marroqui L, et al. PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-alpha and-gamma via IRF1 induction. Ebiomedicine. 2018;36:367–375.
   PubMed Web of Science ®Google Scholar
• Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003;198:63–69.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Matteson EL, et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest. 2003;111:363–370.
   PubMed Web of Science ®Google Scholar
• Stefanski AL, Wiedemann A, Reiter K, et al. Enhanced PD-1 and diminished PD-L1 upregulation capacity mark post-activated lupus B cells. Arthritis Rheumatol. 2019;71:1539–1544.
   PubMedGoogle Scholar
• Curran CS, Gupta S, Sanz I, et al. PD-1 immunobiology in systemic lupus erythematosus. J Autoimmun. 2019;97:1–9.
   PubMed Web of Science ®Google Scholar
• Zhou J, Jin JO, Kawai T, et al. Endogenous programmed death ligand-1 restrains the development and onset of Sjgren’s syndrome in non-obese diabetic mice. Sci Rep. 2016;6:39105.
   PubMed Web of Science ®Google Scholar
• Frigola X, Inman BA, Lohse CM, et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 2011;17:1915–1923.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang Q, Shi B, et al. Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. Cytokine. 2011;56:231–238.
   PubMed Web of Science ®Google Scholar
• Pistillo MP, Carosio R, Banelli B, et al. IFN-gamma upregulates membranous and soluble PD-L1 in mesothelioma cells: potential implications for the clinical response to PD-1/PD-L1 blockade. Cell Mol Immunol. 2019.
   PubMed Web of Science ®Google Scholar
• Okuyama M, Mezawa H, Kawai T, et al. Elevated soluble PD-L1 in pregnant women’s serum suppresses the immune reaction. Front Immunol. 2019;10:86.
   PubMed Web of Science ®Google Scholar
• Chang B, Huang T, Wei H, et al. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2019;68:353–363.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu L, Zhou S, et al. Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas. Hematol Oncol. 2019;37:270–276.
   PubMed Web of Science ®Google Scholar
• Yamagiwa S, Ishikawa T, Waguri N, et al. Increase of soluble programmed cell death ligand 1 in patients with chronic hepatitis C. Int J Med Sci. 2017;14:403–411.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li M, Liu J, et al. sPD-L1 expression is associated with immunosuppression and infectious complications in patients with acute pancreatitis. Scand J Immunol. 2017;86:100–106.
   PubMed Web of Science ®Google Scholar
• Jovanovic D, Roksandic MM, Kotur SJ, et al. Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study. J Thorac Dis. 2018;10:6660–6669.
   PubMed Web of Science ®Google Scholar
• Shi B, Du X, Wang Q, et al. Increased PD-1 on CD4(+)CD28(−) T cell and soluble PD-1 ligand-1 in patients with T2DM: association with atherosclerotic macrovascular diseases. Metabolism. 2013;62:778–785.
   PubMed Web of Science ®Google Scholar
• Pizarro C, Garcia-Diaz DF, Codner E, et al. PD-L1 gene polymorphisms and low serum level of PD-L1 protein are associated to type 1 diabetes in Chile. Diabetes Metab Res Rev. 2014;30:761–766.
   PubMed Web of Science ®Google Scholar
• Dimou P, Wright RD, Budge KL, et al. The human glomerular endothelial cells are potent pro-inflammatory contributors in an in vitro model of lupus nephritis. Sci Rep. 2019;9:8348.
   PubMed Web of Science ®Google Scholar
• Kasagi S, Kawano S, Okazaki T, et al. Anti-programmed cell death 1 antibody reduces CD4 + PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice. J Immunol. 2010;184:2337–2347.
   PubMed Web of Science ®Google Scholar
• Ding H, Wu X, Gao W. PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. Clin Immunol. 2005;115:184–191.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang J, Li J, et al. Expression of B7-H1 in inflammatory renal tubular epithelial cells. Nephron Exp Nephrol. 2005;102:e81–e92.
   PubMedGoogle Scholar
• Cheng Y, Li F, Wang D, et al. Sinomenine inhibits the expression of PDL1 in the peripheral blood mononuclear cells of mesangial proliferative nephritis patients. Mol Med Rep. 2013;7:1223–1228.
   PubMed Web of Science ®Google Scholar
• Schoop R, Wahl P, Le Hir M, et al. Suppressed T-cell activation by IFN-gamma-induced expression of PD-L1 on renal tubular epithelial cells. Nephrol Dial Transplant. 2004;19:2713–2720.
   PubMed Web of Science ®Google Scholar
• Starke A, Lindenmeyer MT, Segerer S, et al. Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses. Kidney Int. 2010;78:38–47.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang J, Guo G, et al. Induced B7-H1 expression on human renal tubular epithelial cells by the sublytic terminal complement complex C5b-9. Mol Immunol. 2009;46:375–383.
   PubMed Web of Science ®Google Scholar
• Starke A, Wuthrich RP, Waeckerle-Men Y. TGF-beta treatment modulates PD-L1 and CD40 expression in proximal renal tubular epithelial cells and enhances CD8 cytotoxic T-cell responses. Nephron Exp Nephrol. 2007;107:e22–e29.
   PubMedGoogle Scholar
• de Haij S, Woltman AM, Trouw LA, et al. Renal tubular epithelial cells modulate T-cell responses via ICOS-L and B7-H1. Kidney Int. 2005;68:2091–2102.
   PubMed Web of Science ®Google Scholar
• Sampangi S, Wang X, Beagley KW, et al. Human proximal tubule epithelial cells modulate autologous B-cell function. Nephrol Dial Transplant. 2015;30:1674–1683.
   PubMed Web of Science ®Google Scholar
• Kassianos AJ, Sampangi S, Wang X, et al. Human proximal tubule epithelial cells modulate autologous dendritic cell function. Nephrol Dial Transplant. 2013;28:303–312.
   PubMed Web of Science ®Google Scholar
• Sampangi S, Kassianos AJ, Wang X, et al. The mechanisms of human renal epithelial cell modulation of autologous dendritic cell phenotype and function. PLoS One. 2015;10:e134688.
   Web of Science ®Google Scholar
• Chen Y, Li J, Zhang J, et al. Sinomenine inhibits B7-H1 and B7-DC expression on human renal tubular epithelial cells. Int Immunopharmacol. 2005;5:1446–1457.
   PubMed Web of Science ®Google Scholar
• Demmers MW, Korevaar SS, Roemeling-van RM, et al. Human renal tubular epithelial cells suppress alloreactive T cell proliferation. Clin Exp Immunol. 2015;179:509–519.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang J, Li J, et al. Triptolide inhibits B7-H1 expression on proinflammatory factor activated renal tubular epithelial cells by decreasing NF-kappaB transcription. Mol Immunol. 2006;43:1088–1098.
   PubMed Web of Science ®Google Scholar
• Grywalska E, Smarz-Widelska I, Krasowska-Zajac E, et al. The PD-1/PD-L1 inhibitory pathway is altered in primary glomerulonephritides. Arch Immunol Ther Exp (Warsz). 2018;66:133–143.
   PubMed Web of Science ®Google Scholar
• Sung SJ, Ge Y, Dai C, et al. Dependence of glomerulonephritis induction on novel intraglomerular alternatively activated bone marrow-derived macrophages and Mac-1 and PD-L1 in lupus-prone NZM2328 mice. J Immunol. 2017;198:2589–2601.
   PubMed Web of Science ®Google Scholar
• Kawamoto E, Masui-Ito A, Eguchi A, et al. Integrin and PD-1 ligand expression on circulating extracellular vesicles in systemic inflammatory response syndrome and sepsis. Shock. 2019;52:13–22.
   PubMed Web of Science ®Google Scholar
• Yu L, Huang A, Wang W, et al. Relatively increased number of liver Foxp(3+) regulatory T cells against hepatic lesions in murine lupus. J Huazhong Univ Sci Technol [Med Sci]. 2011;31:476–481.
   PubMedGoogle Scholar
• Ding H, Wu X, Wu J, et al. Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice. Clin Immunol. 2006;118:258–267.
   PubMed Web of Science ®Google Scholar
• Zhou H, Xiong L, Wang Y, et al. Treatment of murine lupus with PD-LIg. Mol Immunol. 2016;162:1–8.
   Google Scholar
• Liao W, Zheng H, Wu S, et al. The systemic activation of programmed death 1-PD-L1 axis protects systemic lupus erythematosus model from nephritis. Am J Nephrol. 2017;46:371–379.
   PubMed Web of Science ®Google Scholar
• Jaworska K, Ratajczak J, Huang L, et al. Both PD-1 ligands protect the kidney from ischemia reperfusion injury. J Immunol. 2015;194:325–333.
   PubMed Web of Science ®Google Scholar
• Menke J, Lucas JA, Zeller GC, et al. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles. J Immunol. 2007;179:7466–7477.
   PubMed Web of Science ®Google Scholar
• Neumann K, Ostmann A, Breda PC, et al. The co-inhibitory molecule PD-L1 contributes to regulatory T cell-mediated protection in murine crescentic glomerulonephritis. Sci Rep. 2019;9:2038.
   PubMed Web of Science ®Google Scholar
• Ooi JD, Li M, Kourkoutzelos K, et al. Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis. Nephrology (Carlton). 2015;20:892–898.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Gueutin V, Gharbi C, et al. Kidney injuries related to ipilimumab. Invest New Drugs. 2014;32:769–773.
   PubMed Web of Science ®Google Scholar
• Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90:638–647.
   PubMed Web of Science ®Google Scholar
• Murakami N, Borges TJ, Yamashita M, et al. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J. 2016;9:411–417.
   PubMed Web of Science ®Google Scholar
• Cassol C, Satoskar A, Lozanski G, et al. Anti-PD-1 immunotherapy may induce interstitial nephritis with increased tubular epithelial expression of PD-L1. Kidney Int Rep. 2019;4:1152–1160.
   PubMed Web of Science ®Google Scholar
• Shingarev R, Glezerman IG. Kidney complications of immune checkpoint inhibitors: a review. Am J Kidney Dis. 2019;74:529–537.
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Colston E, Yende S, et al. Immune checkpoint inhibition in sepsis: a phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 antibody (BMS-936559). Crit Care Med. 2019;47:632–642.
   PubMed Web of Science ®Google Scholar
• Chang HN, Liu BY, Qi YK, et al. Blocking of the PD-1/PD-L1 interaction by a D-peptide antagonist for cancer immunotherapy. Angew Chem Int Ed Engl. 2015;54:11760–11764.
   PubMed Web of Science ®Google Scholar